Introduction Antibody–drug conjugates (ADCs) have established roles in selected lymphoma settings, but the maturity, subtype distribution, and platform diversity of the clinical pipeline remain unclear. We mapped interventional trials to evaluate development trends, evidence maturity, molecular architecture, combinatio...
Hengrui Zhang, Jincheng Li, Han-Xi Yan et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.